Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Overview
General Medicine
Affiliations
We have recently shown that expression of the enzyme indoleamine 2, 3-dioxygenase (IDO) during murine pregnancy is required to prevent rejection of the allogeneic fetus by maternal T cells. In addition to their role in pregnancy, IDO-expressing cells are widely distributed in primary and secondary lymphoid organs. Here we show that monocytes that have differentiated under the influence of macrophage colony-stimulating factor acquire the ability to suppress T cell proliferation in vitro via rapid and selective degradation of tryptophan by IDO. IDO was induced in macrophages by a synergistic combination of the T cell-derived signals IFN-gamma and CD40-ligand. Inhibition of IDO with the 1-methyl analogue of tryptophan prevented macrophage-mediated suppression. Purified T cells activated under tryptophan-deficient conditions were able to synthesize protein, enter the cell cycle, and progress normally through the initial stages of G1, including upregulation of IL-2 receptor and synthesis of IL-2. However, in the absence of tryptophan, cell cycle progression halted at a mid-G1 arrest point. Restoration of tryptophan to arrested cells was not sufficient to allow further cell cycle progression nor was costimulation via CD28. T cells could exit the arrested state only if a second round of T cell receptor signaling was provided in the presence of tryptophan. These data reveal a novel mechanism by which antigen-presenting cells can regulate T cell activation via tryptophan catabolism. We speculate that expression of IDO by certain antigen presenting cells in vivo allows them to suppress unwanted T cell responses.
Myeloid cells: key players in tumor microenvironments.
Hua Q, Li Z, Weng Y, Wu Y, Zheng L Front Med. 2025; .
PMID: 40048137 DOI: 10.1007/s11684-025-1124-8.
Huang L, Liu Y, Shi Y, Sun Q, Li H, Sun C Discov Oncol. 2025; 16(1):206.
PMID: 39969635 PMC: 11839968. DOI: 10.1007/s12672-025-01929-1.
Gorria T, Sierra-Boada M, Rojas M, Figueras C, Marin S, Madurga S Cancers (Basel). 2025; 17(3).
PMID: 39941865 PMC: 11815897. DOI: 10.3390/cancers17030498.
Gu T, Qi H, Wang J, Sun L, Su Y, Hu H Discov Oncol. 2025; 16(1):163.
PMID: 39934467 PMC: 11813846. DOI: 10.1007/s12672-025-01930-8.
Advances and prospects of cell-penetrating peptides in tumor immunotherapy.
Yang D, Liu B, Sha H Sci Rep. 2025; 15(1):3392.
PMID: 39870681 PMC: 11772771. DOI: 10.1038/s41598-025-86130-8.